Star Metro - Vanta Announces Closing of First Tranche of Private Placement and Board of Directors Update

The securities issued under the Private Placement will be subject to a statutory hold period expiring December 22, 2026.

The Private Placement remains ongoing following the closing of the First Tranche. The Company expects to close the remaining portion of the Private Placement, in whole or in part, in one or more additional tranches on or before October 5, 2026, subject to compliance with the policies of the Canadian Securities Exchange.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or under any U.S. state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act and applicable state securities laws.

Board of Directors Update

The Company also announces, that Mr. Norman John Campbell has resigned from the Company's board of directors, effective August 21, 2026, as he transitions to a new professional opportunity as a partner in an asset management firm and seeks to avoid potential conflicts associated with his new role.

The Company extends its sincere appreciation to Mr. Campbell for his longstanding service and contributions to Vanta and wishes him continued success in this next chapter of his career.

Following Mr. Campbell's resignation, Vanta's board of directors is comprised of four members, including two independent directors and two non-independent directors.

About Vanta Holdings Inc.

Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC0, WKN:A4205J) is a consumer health sciences and longevity company advancing an integrated ecosystem of U.S.-focused peptide therapy, nutraceutical, and premium hydration products centered on preventative wellness and healthspan extension, positioning the Company to participate in the rapidly expanding longevity economy.

Vanta is advancing a U.S.-focused telehealth-enabled peptide therapy and longevity platform leveraging commercialization infrastructure and FDA-registered 503A and 503B compounding pharmacy relationships to pursue initiatives across recovery, metabolic wellness, performance optimization, and healthy aging categories.

Through its Vanta brand and select private-label partnerships, the Company develops, manufactures, and distributes premium hydration and longevity-oriented nutraceutical products, including, without limitation, its flagship proprietary Blackwater and BlackPowder product portfolio featuring bioactive compounds, trace mineral complexes, and patented Fulvic Isolation Technology™ designed to support hydration, mineral replenishment, cellular function, immune function, gut health, nutrient absorption, cognitive function, and broader everyday wellness-focused applications aligned with growing consumer demand for functional health optimization products. Vanta's vertically integrated operations include ownership of a natural alkaline spring water aquifer and a 40,000-square-foot, Health Canada and HACCP-certified manufacturing facility situated in the mountains of British Columbia.

On behalf of the Board of Directors:

Martino Ciambrelli, Director
[email protected]
604-449-1816

Disclaimer for Forward-Looking Information

This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements in this release relate to, among other things: the expected closing of the remaining portion of the Private Placement, in whole or in part, in one or more additional tranches on or before October 5, 2026; the advancement of the Company's integrated consumer health sciences and longevity platform; the advancement of the Company's U.S.-focused telehealth-enabled peptide therapy and longevity platform; and the Company's pursuit of related commercialization initiatives across recovery, metabolic wellness, performance optimization, and healthy aging categories. Forward-looking statements are based on management's current expectations, estimates, assumptions, and projections that are believed to be reasonable as of the date of this news release, including assumptions regarding the Company's ability to complete additional tranches of the Private Placement; compliance with applicable Canadian Securities Exchange policies and other regulatory requirements; the availability of sufficient capital, personnel, infrastructure, and other resources to advance the Company's business initiatives; the Company's ability to maintain and utilize its relationships with telehealth providers, compounding pharmacies, and other commercial partners; and prevailing regulatory, economic, business, and market conditions. However, such statements are inherently subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the remaining portion of the Private Placement may not close when anticipated, in the amounts anticipated, or at all; the Company's ability to comply with applicable Canadian Securities Exchange policies and regulatory requirements; the availability of sufficient financing and other resources to advance the Company's business initiatives; risks associated with advancing the Company's integrated consumer health sciences and longevity platform and U.S.-focused telehealth-enabled peptide therapy and longevity platform; the Company's reliance on third-party telehealth providers, compounding pharmacies, and other commercial partners; changes in applicable healthcare, pharmaceutical, telehealth, consumer product, securities, and other laws and regulations; and general economic, business, market, and capital markets conditions. There can be no assurance that the remaining portion of the Private Placement will close, in whole or in part, on or before October 5, 2026 or at all, or that the Company will successfully advance its integrated consumer health sciences and longevity platform or U.S.-focused telehealth-enabled peptide therapy and longevity platform as currently contemplated. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information to reflect new information, future events, or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and are encouraged to consult the Company's continuous disclosure filings available under its profile on SEDAR+ for additional risk factors and further information.

SOURCE: Vanta Holdings Inc.

View the original press release on ACCESS Newswire

X.Boucher--SMC